FibroGen, Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 38,636 shares of the company’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $51.67, for a total transaction of $1,996,322.12. Following the completion of the sale, the chief executive officer now owns 3,297,655 shares of the company’s stock, valued at approximately $170,389,833.85. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of FibroGen, Inc (NASDAQ FGEN) traded up 0.58% during trading on Friday, reaching $52.40. 1,462,946 shares of the company were exchanged. The firm’s market cap is $3.73 billion. The stock’s 50-day moving average is $42.78 and its 200-day moving average is $31.87. FibroGen, Inc has a 52-week low of $15.60 and a 52-week high of $52.70.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The firm had revenue of $29.00 million for the quarter, compared to the consensus estimate of $34.80 million. Equities research analysts predict that FibroGen, Inc will post ($1.80) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Thomas B. Neff Sells 38,636 Shares of FibroGen, Inc (FGEN) Stock” was published by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/15/thomas-b-neff-sells-38636-shares-of-fibrogen-inc-fgen-stock.html.

A number of institutional investors and hedge funds have recently bought and sold shares of FGEN. BlackRock Inc. increased its stake in FibroGen by 29,724.1% in the first quarter. BlackRock Inc. now owns 4,454,819 shares of the biopharmaceutical company’s stock valued at $109,811,000 after purchasing an additional 4,439,882 shares in the last quarter. FMR LLC increased its stake in FibroGen by 96.9% in the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after purchasing an additional 1,641,423 shares in the last quarter. EcoR1 Capital LLC increased its stake in FibroGen by 3,674.1% in the second quarter. EcoR1 Capital LLC now owns 1,585,457 shares of the biopharmaceutical company’s stock valued at $51,210,000 after purchasing an additional 1,543,448 shares in the last quarter. Janus Henderson Group PLC bought a new stake in FibroGen in the second quarter valued at $45,633,000. Finally, Vanguard Group Inc. increased its stake in FibroGen by 15.1% in the second quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock valued at $187,612,000 after purchasing an additional 761,421 shares in the last quarter. 47.49% of the stock is owned by hedge funds and other institutional investors.

FGEN has been the subject of a number of recent analyst reports. Stifel Nicolaus restated a “buy” rating and issued a $38.00 price objective (up previously from $32.00) on shares of FibroGen in a research report on Thursday, June 22nd. Jefferies Group LLC restated a “buy” rating and issued a $75.00 price objective on shares of FibroGen in a research report on Tuesday. Citigroup Inc. restated a “buy” rating and issued a $48.00 price objective on shares of FibroGen in a research report on Monday, June 26th. BidaskClub cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Goldman Sachs Group, Inc. (The) cut shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective for the company. in a research report on Friday, July 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. FibroGen has a consensus rating of “Buy” and a consensus target price of $60.17.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.